Active Pharmaceutical Ingredient (API) Market in US 2024-2028

Description

List of Tables

The active pharmaceutical ingredient (API) market in US is forecasted to grow by USD 16.51 bn during 2023-2028, accelerating at a CAGR of 7.87% during the forecast period. The report on the active pharmaceutical ingredient (API) market in US provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by an increasing number of type II drug master files (DMF), the growing prevalence of chronic conditions, and increasing demand for biopharmaceuticals and biosimilars.

Technavio's active pharmaceutical ingredient (API) market in US is segmented as below:

Market Scope
Base Year	2024
End Year	2028
Series Year	2024-2028
Growth Momentum	Accelerate
YOY 2024	6.79%
CAGR	7.87%
Incremental Value	$16.51bn

By Type

Captive API
Contract API

By Product

Generic
Innovative

By Application

Oncology
Cardiovascular diseases
Diabetes
Communicable diseases
Orthopedic and others

This study identifies the paradigm shift in API manufacturing as one of the prime reasons driving the active pharmaceutical ingredient (API) market in US growth during the next few years. Also, increasing patent exercises and a growing focus on the production of high-value APIs will lead to sizable demand in the market.

The report on the active pharmaceutical ingredient (API) market in US covers the following areas:

Active pharmaceutical ingredient (API) market in US sizing
Active pharmaceutical ingredient (API) market in US forecast
Active pharmaceutical ingredient (API) market in US industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading active pharmaceutical ingredient (API) market in US vendors that include AbbVie Inc., Amneal Pharmaceuticals Inc., Apotex Inc., Aurobindo Pharma Ltd., Bristol Myers Squibb Co., Cadila Pharmaceuticals Ltd., Cambrex Corp., Cipla Ltd., Dr Reddys Laboratories Ltd., GlaxoSmithKline Plc, Koninklijke DSM NV, Lupin Ltd., Merck KGaA, Novartis AG, Pfizer Inc., Sanofi SA, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Thermo Fisher Scientific Inc., and Viatris Inc.. Also, the active pharmaceutical ingredient (API) market in US analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources through an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

Product Code: IRTNTR77525

1 Executive Summary

1.1 Market overview
Exhibit 01: Executive Summary - Chart on Market Overview
Exhibit 02: Executive Summary - Data Table on Market Overview
Exhibit 03: Executive Summary - Chart on Country Market Characteristics
Exhibit 04: Executive Summary - Chart on Market Segmentation by Type
Exhibit 05: Executive Summary - Chart on Market Segmentation by Product
Exhibit 06: Executive Summary - Chart on Market Segmentation by Application
Exhibit 07: Executive Summary - Chart on Vendor Market Positioning

2 Market Landscape

2.1 Market ecosystem
Exhibit 08: Parent market
Exhibit 09: Market Characteristics

3 Market Sizing

3.1 Market definition
Exhibit 10: Offerings of vendors included in the market definition
3.2 Market segment analysis
Exhibit 11: Market segments
3.3 Market size 2023
3.4 Market outlook: Forecast for 2023-2028
Exhibit 12: Chart on US - Market size and forecast 2023-2028 ($ billion)
Exhibit 13: Data Table on US - Market size and forecast 2023-2028 ($ billion)
Exhibit 14: Chart on US: Year-over-year growth 2023-2028 (%)
Exhibit 15: Data Table on US: Year-over-year growth 2023-2028 (%)

4 Historic Market Size

4.1 Active pharmaceutical ingredient (API) market in US 2018 - 2022
Exhibit 16: Historic Market Size - Data Table on active pharmaceutical ingredient (api) market in US 2018 - 2022 ($ billion)
4.2 Type Segment Analysis 2018 - 2022
Exhibit 17: Historic Market Size - Type Segment 2018 - 2022 ($ billion)
4.3 Product Segment Analysis 2018 - 2022
Exhibit 18: Historic Market Size - Product Segment 2018 - 2022 ($ billion)
4.4 Application Segment Analysis 2018 - 2022
Exhibit 19: Historic Market Size - Application Segment 2018 - 2022 ($ billion)

5 Five Forces Analysis

5.1 Five forces summary
Exhibit 20: Five forces analysis - Comparison between 2023 and 2028
5.2 Bargaining power of buyers
Exhibit 21: Chart on Bargaining power of buyers - Impact of key factors 2023 and 2028
5.3 Bargaining power of suppliers
Exhibit 22: Bargaining power of suppliers - Impact of key factors in 2023 and 2028
5.4 Threat of new entrants
Exhibit 23: Threat of new entrants - Impact of key factors in 2023 and 2028
5.5 Threat of substitutes
Exhibit 24: Threat of substitutes - Impact of key factors in 2023 and 2028
5.6 Threat of rivalry
Exhibit 25: Threat of rivalry - Impact of key factors in 2023 and 2028
5.7 Market condition
Exhibit 26: Chart on Market condition - Five forces 2023 and 2028

6 Market Segmentation by Type

6.1 Market segments
Exhibit 27: Chart on Type - Market share 2023-2028 (%)
Exhibit 28: Data Table on Type - Market share 2023-2028 (%)
6.2 Comparison by Type
Exhibit 29: Chart on Comparison by Type
Exhibit 30: Data Table on Comparison by Type
6.3 Captive API - Market size and forecast 2023-2028
Exhibit 31: Chart on Captive API - Market size and forecast 2023-2028 ($ billion)
Exhibit 32: Data Table on Captive API - Market size and forecast 2023-2028 ($ billion)
Exhibit 33: Chart on Captive API - Year-over-year growth 2023-2028 (%)
Exhibit 34: Data Table on Captive API - Year-over-year growth 2023-2028 (%)
6.4 Contract API - Market size and forecast 2023-2028
Exhibit 35: Chart on Contract API - Market size and forecast 2023-2028 ($ billion)
Exhibit 36: Data Table on Contract API - Market size and forecast 2023-2028 ($ billion)
Exhibit 37: Chart on Contract API - Year-over-year growth 2023-2028 (%)
Exhibit 38: Data Table on Contract API - Year-over-year growth 2023-2028 (%)
6.5 Market opportunity by Type
Exhibit 39: Market opportunity by Type ($ billion)
Exhibit 40: Data Table on Market opportunity by Type ($ billion)

7 Market Segmentation by Product

7.1 Market segments
Exhibit 41: Chart on Product - Market share 2023-2028 (%)
Exhibit 42: Data Table on Product - Market share 2023-2028 (%)
7.2 Comparison by Product
Exhibit 43: Chart on Comparison by Product
Exhibit 44: Data Table on Comparison by Product
7.3 Generic - Market size and forecast 2023-2028
Exhibit 45: Chart on Generic - Market size and forecast 2023-2028 ($ billion)
Exhibit 46: Data Table on Generic - Market size and forecast 2023-2028 ($ billion)
Exhibit 47: Chart on Generic - Year-over-year growth 2023-2028 (%)
Exhibit 48: Data Table on Generic - Year-over-year growth 2023-2028 (%)
7.4 Innovative - Market size and forecast 2023-2028
Exhibit 49: Chart on Innovative - Market size and forecast 2023-2028 ($ billion)
Exhibit 50: Data Table on Innovative - Market size and forecast 2023-2028 ($ billion)
Exhibit 51: Chart on Innovative - Year-over-year growth 2023-2028 (%)
Exhibit 52: Data Table on Innovative - Year-over-year growth 2023-2028 (%)
7.5 Market opportunity by Product
Exhibit 53: Market opportunity by Product ($ billion)
Exhibit 54: Data Table on Market opportunity by Product ($ billion)

8 Market Segmentation by Application

8.1 Market segments
Exhibit 55: Chart on Application - Market share 2023-2028 (%)
Exhibit 56: Data Table on Application - Market share 2023-2028 (%)
8.2 Comparison by Application
Exhibit 57: Chart on Comparison by Application
Exhibit 58: Data Table on Comparison by Application
8.3 Oncology - Market size and forecast 2023-2028
Exhibit 59: Chart on Oncology - Market size and forecast 2023-2028 ($ billion)
Exhibit 60: Data Table on Oncology - Market size and forecast 2023-2028 ($ billion)
Exhibit 61: Chart on Oncology - Year-over-year growth 2023-2028 (%)
Exhibit 62: Data Table on Oncology - Year-over-year growth 2023-2028 (%)
8.4 Cardiovascular diseases - Market size and forecast 2023-2028
Exhibit 63: Chart on Cardiovascular diseases - Market size and forecast 2023-2028 ($ billion)
Exhibit 64: Data Table on Cardiovascular diseases - Market size and forecast 2023-2028 ($ billion)
Exhibit 65: Chart on Cardiovascular diseases - Year-over-year growth 2023-2028 (%)
Exhibit 66: Data Table on Cardiovascular diseases - Year-over-year growth 2023-2028 (%)
8.5 Diabetes - Market size and forecast 2023-2028
Exhibit 67: Chart on Diabetes - Market size and forecast 2023-2028 ($ billion)
Exhibit 68: Data Table on Diabetes - Market size and forecast 2023-2028 ($ billion)
Exhibit 69: Chart on Diabetes - Year-over-year growth 2023-2028 (%)
Exhibit 70: Data Table on Diabetes - Year-over-year growth 2023-2028 (%)
8.6 Communicable diseases - Market size and forecast 2023-2028
Exhibit 71: Chart on Communicable diseases - Market size and forecast 2023-2028 ($ billion)
Exhibit 72: Data Table on Communicable diseases - Market size and forecast 2023-2028 ($ billion)
Exhibit 73: Chart on Communicable diseases - Year-over-year growth 2023-2028 (%)
Exhibit 74: Data Table on Communicable diseases - Year-over-year growth 2023-2028 (%)
8.7 Orthopedic and others - Market size and forecast 2023-2028
Exhibit 75: Chart on Orthopedic and others - Market size and forecast 2023-2028 ($ billion)
Exhibit 76: Data Table on Orthopedic and others - Market size and forecast 2023-2028 ($ billion)
Exhibit 77: Chart on Orthopedic and others - Year-over-year growth 2023-2028 (%)
Exhibit 78: Data Table on Orthopedic and others - Year-over-year growth 2023-2028 (%)
8.8 Market opportunity by Application
Exhibit 79: Market opportunity by Application ($ billion)
Exhibit 80: Data Table on Market opportunity by Application ($ billion)

9 Customer Landscape

9.1 Customer landscape overview
Exhibit 81: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

10 Drivers, Challenges, and Trends

10.1 Market drivers
10.2 Market challenges
10.3 Impact of drivers and challenges
Exhibit 82: Impact of drivers and challenges in 2023 and 2028
10.4 Market trends

11 Vendor Landscape

11.1 Overview
11.2 Vendor landscape
Exhibit 83: Overview on Criticality of inputs and Factors of differentiation
11.3 Landscape disruption
Exhibit 84: Overview on factors of disruption
11.4 Industry risks
Exhibit 85: Impact of key risks on business

12 Vendor Analysis

12.1 Vendors covered
Exhibit 86: Vendors covered
12.2 Market positioning of vendors
Exhibit 87: Matrix on vendor position and classification
12.3 AbbVie Inc.
Exhibit 88: AbbVie Inc. - Overview
Exhibit 89: AbbVie Inc. - Product / Service
Exhibit 90: AbbVie Inc. - Key news
Exhibit 91: AbbVie Inc. - Key offerings
12.4 Amneal Pharmaceuticals Inc.
Exhibit 92: Amneal Pharmaceuticals Inc. - Overview
Exhibit 93: Amneal Pharmaceuticals Inc. - Business segments
Exhibit 94: Amneal Pharmaceuticals Inc. - Key news
Exhibit 95: Amneal Pharmaceuticals Inc. - Key offerings
Exhibit 96: Amneal Pharmaceuticals Inc. - Segment focus
12.5 Aurobindo Pharma Ltd.
Exhibit 97: Aurobindo Pharma Ltd. - Overview
Exhibit 98: Aurobindo Pharma Ltd. - Product / Service
Exhibit 99: Aurobindo Pharma Ltd. - Key offerings
12.6 Cadila Pharmaceuticals Ltd.
Exhibit 100: Cadila Pharmaceuticals Ltd. - Overview
Exhibit 101: Cadila Pharmaceuticals Ltd. - Product / Service
Exhibit 102: Cadila Pharmaceuticals Ltd. - Key offerings
12.7 Cipla Ltd.
Exhibit 103: Cipla Ltd. - Overview
Exhibit 104: Cipla Ltd. - Business segments
Exhibit 105: Cipla Ltd. - Key news
Exhibit 106: Cipla Ltd. - Key offerings
Exhibit 107: Cipla Ltd. - Segment focus
12.8 Dr Reddys Laboratories Ltd.
Exhibit 108: Dr Reddys Laboratories Ltd. - Overview
Exhibit 109: Dr Reddys Laboratories Ltd. - Business segments
Exhibit 110: Dr Reddys Laboratories Ltd. - Key offerings
Exhibit 111: Dr Reddys Laboratories Ltd. - Segment focus
12.9 GlaxoSmithKline Plc
Exhibit 112: GlaxoSmithKline Plc - Overview
Exhibit 113: GlaxoSmithKline Plc - Business segments
Exhibit 114: GlaxoSmithKline Plc - Key news
Exhibit 115: GlaxoSmithKline Plc - Key offerings
Exhibit 116: GlaxoSmithKline Plc - Segment focus
12.10 Koninklijke DSM NV
Exhibit 117: Koninklijke DSM NV - Overview
Exhibit 118: Koninklijke DSM NV - Business segments
Exhibit 119: Koninklijke DSM NV - Key news
Exhibit 120: Koninklijke DSM NV - Key offerings
Exhibit 121: Koninklijke DSM NV - Segment focus
12.11 Lupin Ltd.
Exhibit 122: Lupin Ltd. - Overview
Exhibit 123: Lupin Ltd. - Product / Service
Exhibit 124: Lupin Ltd. - Key news
Exhibit 125: Lupin Ltd. - Key offerings
12.12 Novartis AG
Exhibit 126: Novartis AG - Overview
Exhibit 127: Novartis AG - Business segments
Exhibit 128: Novartis AG - Key offerings
Exhibit 129: Novartis AG - Segment focus
12.13 Pfizer Inc.
Exhibit 130: Pfizer Inc. - Overview
Exhibit 131: Pfizer Inc. - Product / Service
Exhibit 132: Pfizer Inc. - Key news
Exhibit 133: Pfizer Inc. - Key offerings
12.14 Sanofi SA
Exhibit 134: Sanofi SA - Overview
Exhibit 135: Sanofi SA - Business segments
Exhibit 136: Sanofi SA - Key news
Exhibit 137: Sanofi SA - Key offerings
Exhibit 138: Sanofi SA - Segment focus
12.15 Sun Pharmaceutical Industries Ltd.
Exhibit 139: Sun Pharmaceutical Industries Ltd. - Overview
Exhibit 140: Sun Pharmaceutical Industries Ltd. - Product / Service
Exhibit 141: Sun Pharmaceutical Industries Ltd. - Key news
Exhibit 142: Sun Pharmaceutical Industries Ltd. - Key offerings
12.16 Teva Pharmaceutical Industries Ltd.
Exhibit 143: Teva Pharmaceutical Industries Ltd. - Overview
Exhibit 144: Teva Pharmaceutical Industries Ltd. - Business segments
Exhibit 145: Teva Pharmaceutical Industries Ltd. - Key news
Exhibit 146: Teva Pharmaceutical Industries Ltd. - Key offerings
Exhibit 147: Teva Pharmaceutical Industries Ltd. - Segment focus
12.17 Viatris Inc.
Exhibit 148: Viatris Inc. - Overview
Exhibit 149: Viatris Inc. - Business segments
Exhibit 150: Viatris Inc. - Key news
Exhibit 151: Viatris Inc. - Key offerings
Exhibit 152: Viatris Inc. - Segment focus

13 Appendix

13.1 Scope of the report
13.2 Inclusions and exclusions checklist
Exhibit 153: Inclusions checklist
Exhibit 154: Exclusions checklist
13.3 Currency conversion rates for US$
Exhibit 155: Currency conversion rates for US$
13.4 Research methodology
Exhibit 156: Research methodology
Exhibit 157: Validation techniques employed for market sizing
Exhibit 158: Information sources
13.5 List of abbreviations
Exhibit 159: List of abbreviations